Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pigment Disorders Clear all
Withdrawn Phase 2 Interventional

Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation

NCT06473974
View directory record Official record
Conditions
Facial Hyperpigmentation
Interventions
Test cosmetic product
Drug
Lead sponsor
Kayuraeffect, LLP
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Miami Lakes, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease

NCT01656746
View directory record Official record
Conditions
Adenomatous Polyp, Crohn Disease, Familial Adenomatous Polyposis, Hereditary Intestinal Polyposis Syndrome, Recurrent Colon Cancer, Stage I Colon Cancer, Stage IIA Colon Cancer, Stage IIB Colon Cancer, Stage IIC Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer
Interventions
therapeutic laparoscopic surgery
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 24, 2026, 3:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cause of Pigment Dispersion Syndrome

NCT00005919
View directory record Official record
Conditions
Glaucoma, Healthy, Pigment Dispersion Syndrome
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 24, 2026, 3:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Gut and Skin Microbiome in Vitiligo Disease Progression

NCT03577327
View directory record Official record
Conditions
Vitiligo, Healthy
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 24, 2026, 3:14 AM EDT
Completed No phase listed Observational

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

NCT00040222
View directory record Official record
Conditions
Familial Ovarian Cancer, Familial Breast Cancer, BRCA1-associate Malignancies, BRCA2-associated Malignancies
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

TCA 15% Chemical Peel for Improvement in Hand Lentigines

NCT05471947
View directory record Official record
Conditions
Photoaging, Lentigo
Interventions
15% Trichloroacetic acid + 3% glycolic acid
Drug
Lead sponsor
Main Line Center for Laser Surgery
Other
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 24, 2026, 3:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

NCT02286089
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
OpRegen
Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
3
States / cities
San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lutronic Infini and LaseMD Systems in Combination Treatment

NCT03409965
View directory record Official record
Conditions
Face and Neck Wrinkles, Texture, Pigmentation
Interventions
Lutronic Infini System, Lutronic LaseMD System
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Vista, California • Santa Rosa Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma

NCT02730819
View directory record Official record
Conditions
Melasma
Interventions
Illuminate Cream
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Sep 24, 2026, 3:14 AM EDT
Completed No phase listed Observational

Hereditary Colorectal and Associated Tumor Registry Study

NCT00633607
View directory record Official record
Conditions
Lynch Syndrome, FAP, Hereditary Diffuse Gastric Cancer, Juvenile Polyposis Syndrome, Peutz-Jeghers Syndrome
Interventions
Research Registry
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 100 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 24, 2026, 3:14 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy

NCT03167203
View directory record Official record
Conditions
Macular Degenerative Disease
Interventions
Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells
Biological
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 24, 2026, 3:14 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Neonatal Pulse Oximetry Disparities Due to Skin Pigmentation

NCT06063148
View directory record Official record
Conditions
Skin Pigment, Pulse Oximetry
Interventions
Enrolled Participant
Device
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 10 Days
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Sacramento, California • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 24, 2026, 3:14 AM EDT
Withdrawn Phase 1 Interventional

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

NCT04500548
View directory record Official record
Conditions
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Primary Central Nervous System Neoplasm, Xeroderma Pigmentosum
Interventions
Biospecimen Collection, Ipilimumab, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 24, 2026, 3:14 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

NCT05692596
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis, BRCA Mutation, Lynch Syndrome, FAP, Familial Atypical Multiple Mole-Melanoma, PALB2 Gene Mutation, Peutz-Jeghers Syndrome, Ataxia Telangiectasia
Interventions
Data collection
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for Vitiligo

NCT05053022
View directory record Official record
Conditions
Vitiligo
Interventions
Skinpen Precision System
Device
Lead sponsor
Crown Laboratories, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Cutaneous Effects of Deep Ultraviolet A +/- High-Energy Visible Blue Light Exposure

NCT06654102
View directory record Official record
Conditions
Skin Pigmentation, Photobiology
Interventions
Deep UVA Irradiation, Deep UVA+HEV Blue Light Irradiation
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Union City, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 24, 2026, 3:14 AM EDT
Terminated Phase 1 Interventional

iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)

NCT01334255
View directory record Official record
Conditions
Pigment Epithelial Detachment
Interventions
iSONEP (sonepcizumab/LT1009)
Drug
Lead sponsor
Lpath, Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Winter Haven, Florida • West Mifflin, Pennsylvania • West Columbia, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma

NCT02095756
View directory record Official record
Conditions
Melasma
Interventions
755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy), Lytera Skin Brightening System (Non-hydroquinone topical therapy)
Other
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Tofacitinib for Immune Skin Conditions in Down Syndrome

NCT04246372
View directory record Official record
Conditions
Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa, Vitiligo, Psoriasis
Interventions
Tofacitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 24, 2026, 3:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

NCT00587132
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Synthetic Human Secretin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Not applicable Interventional

The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism

NCT02200263
View directory record Official record
Conditions
Ocular Albinism (OA), Oculocutaneous Albinism (OCA)
Interventions
Lutein plus Zeaxanthin, Placebo
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Sep 24, 2026, 3:14 AM EDT
Completed Phase 1 Interventional

Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)

NCT01521793
View directory record Official record
Conditions
LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)
Interventions
QLT091001
Drug
Lead sponsor
QLT Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Sep 24, 2026, 3:14 AM EDT
Withdrawn Phase 2 Interventional

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

NCT00514982
View directory record Official record
Conditions
Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions
Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 24, 2026, 3:14 AM EDT
Completed No phase listed Observational

Pancreatic Cancer Early Detection Program

NCT02206360
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma, Familial Pancreatic Cancer, BRCA 1/2, HNPCC, Lynch Syndrome, Hereditary Pancreatitis, FAMMM, Familial Atypical Multiple Mole Melanoma, Peutz Jeghers Syndrome
Interventions
Endoscopic Ultrasound, Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
White Plains Hospital
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 24, 2026, 3:14 AM EDT